

# Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

## Type 1 Diabetes - Rapid Access to Intervention Development

RRID:SCR\_000203

Type: Tool

### Proper Citation

Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR\_000203)

### Resource Information

**URL:** <http://www.t1diabetes.nih.gov/t1d-raid/index.shtml>

**Proper Citation:** Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR\_000203)

**Description:** NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDK staff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDK and NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: \* Definition or optimization of dose and schedule for in vivo activity \* Development of pharmacology assays \* Conduct of pharmacology studies with a pre-determined assay \* Acquisition of bulk substance (GMP and non-GMP) \* Scale-up production from lab-scale to clinical-trials lot scale \* Development of suitable formulations \* Development of analytical methods for bulk substances \* Production of dosage forms \* Stability assurance of dosage forms \* Range-finding initial toxicology \* IND-directed toxicology, with correlative pharmacology and histopathology \* Planning of clinical trials \* Regulatory affairs, so that FDA requirements

are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic \* IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials.

**Abbreviations:** T1D-RAID

**Synonyms:** Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID)

**Resource Type:** resource, service resource

**Keywords:** therapeutic, drug, drug development, pharmacogenomics

**Related Condition:** Type 1 diabetes, Diabetes

**Funding:** NCI ;  
NIDDK

**Resource Name:** Type 1 Diabetes - Rapid Access to Intervention Development

**Resource ID:** SCR\_000203

**Alternate IDs:** nlx\_152742

**Record Creation Time:** 20220129T080200+0000

**Record Last Update:** 20260905T133318+0000

---

## Ratings and Alerts

No rating or validation information has been found for Type 1 Diabetes - Rapid Access to Intervention Development .

No alerts have been found for Type 1 Diabetes - Rapid Access to Intervention Development .

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We have not found any literature mentions for this resource.